Skip to main content
Molecure S.A. logo

Molecure S.A. — Investor Relations & Filings

Ticker · MOC ISIN · PLONCTH00011 LEI · 2594003L11V38ZCVKZ09 WAR Professional, scientific and technical activities
Open in API
Filings indexed 179 across all filing types
Latest filing 2026-05-05 Regulatory Filings
Country PL Poland
Listing WAR MOC

About Molecure S.A.

https://molecure.com/

Molecure S.A. is a clinical-stage biotechnology company focused on discovering and developing first-in-class small molecule drugs for diseases with high unmet medical needs. The company utilizes its expertise in medicinal chemistry and biology to identify, validate, and modulate novel protein and mRNA targets. Its therapeutic pipeline is concentrated on oncological, inflammatory, and fibrotic diseases. Molecure operates a proprietary discovery platform for targeting mRNA with small molecules, enabling the development of innovative therapies for previously untreatable conditions.

Recent filings

Filing Released Lang Actions
Informacja o pozytywnej ocenie wniosku Spółki w ramach konkursu na rozwój projektów badawczo-rozwojowych z obszaru medycyny translacyjnej -TRANSMED I [ABM/2024/8] - Content (PL)
Regulatory Filings
2026-05-05 Polish
Podsumowanie subskrypcji akcji zwykłych na okaziciela serii K. - Content (PL)
Share Issue/Capital Change Classification · 1% confidence The document is an official Polish report (Raport bieżący) detailing the completion of a private subscription and issuance of Series K shares, including subscription dates, number of shares issued, issue price, total issuance value, and issuance costs. This is a specific announcement of a new share issue (capital change), matching the definition of ‘Share Issue/Capital Change (Code: SHA)’ rather than a general financing update or other category.
2026-04-16 Polish
Oświadczenie Zarządu o dookreśleniu kapitału zakładowego podwyższonego w drodze emisji akcji serii K. - Content (PL)
Share Issue/Capital Change Classification · 1% confidence The document is a current report by Molecure S.A. announcing the formal notarial filing and statutory amendment reflecting the increase of the company’s share capital by issuing 4,120,631 new Series K shares, updating the nominal share capital and breakdown by series. This is a direct announcement of a share issue and capital change, matching the “Share Issue/Capital Change” (SHA) category.
2026-04-15 Polish
Pismo Audytora KNF
Regulatory Filings Classification · 1% confidence The document is a formal notification from the audit firm UHY ECA Audyt Sp. z o.o. to the Polish Financial Supervision Commission (KNF) and the Polish Audit Oversight Agency regarding the termination of the statutory audit engagement for Molecure S.A. It is not the audit report itself, nor a financial statement, nor any management, dividend, or financing announcement. It is a regulatory notification that does not fit any more specific category, and thus falls under general regulatory filings.
2026-04-02 Polish
Rozwiązanie umowy o badanie i przegląd sprawozdań finansowych za porozumieniem stron w części jaka dotyczy skonsolidowanych sprawozdań finansowych - Content (PL)
Regulatory Filings Classification · 1% confidence The document is an official announcement by Molecure SA regarding the partial termination of its audit engagement agreement with UHY ECA Audyt. It describes changes in audit scope and contractual terms rather than presenting an actual audit report, financial statements, or investor presentation. It is not a full Annual or Interim Report, an Earnings Release, nor a capital/financing or M&A notice. There is no change in shareholding, dividends, or board composition. It does not constitute the audit report itself, so it does not fit the AR category precisely. Therefore, this falls under the fallback category for miscellaneous regulatory announcements.
2026-04-02 Polish
Notyfikacja 19MAR
Director's Dealing Classification · 1% confidence The document is a notification under Article 19(1) of the EU Market Abuse Regulation (MAR) disclosing an insider-related transaction (acquisition of shares) by a person closely related to management. This falls squarely under the Director’s Dealing category, which covers insider trades and personal transactions by directors or related persons.
2026-03-30 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.